Table 1.
Univariate Analysis of Factors Associated with Polycythemia in HIV-Infected Patients
| Cases (N=21) |
Controls (N=42) |
Matched Odds Ratio |
95% CI | P-value | |
|---|---|---|---|---|---|
|
CD4 cell count (mean [SD];
mm3) * |
473 (248) | 450 (237) | 1.02 | 0.92-1.14 | 0.71 |
|
HIV RNA below level of
quantification (%) |
11 (52%) | 25 (60%) | 0.68 | 0.20-2.31 | 0.54 |
|
Log HIV RNA (mean [SD];
copies/ml) ** |
3.56 (0.90) |
3.89 (1.06) |
0.47 | 0.12-1.75 | 0.26 |
| Hepatitis C co-infection (%) | 6 (29%) | 11 (26%) | 1.13 | 0.34-3.70 | 0.84 |
| Cigarette smoking *** | 10 (48%) | 16 (38%) | 1.48 | 0.51-4.30 | 0.47 |
| Zidovudine use *** | 8 (38%) | 8 (19%) | 2.73 | 0.79-9.50 | 0.11 |
| Any testosterone use *** | 14 (67%) | 9 (21%) | 6.55 | 1.83-23.4 | 0.004 |
| Topical testosterone *** | 5 (24%) | 3 (7%) | 3.33 | 0.80-13.9 | 0.099 |
| Intramuscular testosterone *** | 10 (48%) | 6 (14%) | 4.33 | 1.34-14.0 | 0.015 |
*
Odds ratio is per 50 cells/mm3
**
Log HIV RNA was calculated only for subjects with measurable viremia (n = 10 cases and n = 17 controls)
***
Within two months of first elevated hemoglobin in cases or equivalent time point in controls.